“…Unfortunately, studies assessing functional outcomes of apheresis treatment used different outcome measures, usually referring to either the EDSS or its FSS. Reasoning that the most sensitive outcome was likely to be the one that addressed relapse-related disability, several studies primarily assessed changes in the ‘target neurologic deficit’ (TND), defined as the predominant symptom matching the FSS [19,34,35,38,42]. To simplify the statistical analysis, the majority of the reviewed studies classified recovery according to the response categories ‘no, mild, moderate, and marked’ (Table 1) [19,34,35,36,38,41,43,44,45].…”